Living Proof has entered into a global venture with Valeant Pharmaceuticals International, Inc. to develop, distribute and commercialize products for aesthetic dermatology that will be sold exclusively through Valeant’s direct-to-physician channel. The transaction is worth more than $75 million in upfront and milestone payments as well as a 60/40 profit split, according to the companies.  The initial product development efforts in aesthetic dermatology will be based on Living Proof’s proprietary...